NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma
Phase 1
Recruiting
- Conditions
- Malignant Neoplasm of BrainMalignant Neoplasm
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novelwise Pharmaceutical Corporation
- Target Recruit Count
- 79
- Registration Number
- NCT06012695
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
🇨🇳Hualien Tzu Chi Hospital, Hualien City, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung City, Taiwan
© Copyright 2025. All Rights Reserved by MedPath